Key result
LA remodeling, inflammation, and genetics emerge as novel risk factors to improve CHA2DS2-VASc scoring in AF.
Why the study?
Current AF guidelines have grey areas in anticoagulation decisions, omit key parameters like left atrial remodelling, and risk underestimating thrombotic risk in vulnerable patient categories.
Can the incorporation of additional risk factors such as left atrial remodeling, inflammation, and genetics improve thrombotic and hemorrhagic risk estimation compared to the standard CHA2DS2-VASc score in patients with non-valvular atrial fibrillation?
Can the incorporation of additional risk factors such as left atrial remodeling, inflammation, and genetics improve thrombotic and hemorrhagic risk estimation compared to the standard CHA2DS2-VASc score in patients with non-valvular atrial fibrillation?
This review highlights gaps in the current CHA2DS2-VASc score and proposes incorporating additional risk factors like left atrial remodeling, inflammation, and genetics to improve risk stratification in non-valvular atrial fibrillation.
In 10% of ischemic strokes, non-valvular atrial fibrillation (NVAF) is detected retroactively. Milder, or even asymptomatic forms of NVAF have shown high mortality, thrombotic risk, and deterioration of cognitive function. The current guidelines for the diagnosis and treatment of AF contain "grey areas", such as the one related to anticoagulant treatment in men with CHA2DS2-VASc score 1 and women with score 2. Moreover, parameters such as renal function, patient weight or left atrium remodelling are missing from the recommended guidelines scores. Vulnerable categories of patients including the elderly population, high hemorrhagic risk patients or patients with newly diagnosed paroxysmal episodes of atrial high rate at device interrogation are at risk of underestimation of the thrombotic risk. This review presents a systematic exposure of the most important gaps in evaluation of thrombotic and hemorrhagic risk in patients with NVAF. The authors propose new algorithms and risk factors that should be taken into consideration for an accurate thrombotic and hemorrhagic risk estimation, especially in vulnerable categories of patients.
No takes yet. Share an insight, caveat, or question.
Rachieru et al. (2023) studied this question. Left atrium remodeling, inflammation, and genetics are proposed as novel risk factors to improve the CHA2DS2-VASc score for accurate thrombotic risk estimation in atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: